Early management of atrial fibrillation: From imaging to drugs to ablation

Nature Reviews Cardiology

Volumn 7, Issue 6, 2010, Pages 345-354

  Shah, Ashok J ^a   Liu, Xingpeng ^a   Jadidi, Amir S ^a   Haïssaguerre, Michel ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DABIGATRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROPAFENONE; RAMIPRIL; RANOLAZINE; SOTALOL; VERNAKALANT; WARFARIN; XIMELAGATRAN;

BRADYCARDIA; CATHETER ABLATION; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EARLY INTERVENTION; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROARRHYTHMIA; HEART RATE; HEART SURGERY; HEART TAMPONADE; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SINUS RHYTHM; SNEEZING; STROKE; THYROID DISEASE; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DISEASE PROGRESSION; HUMANS; PULMONARY VEINS; STROKE; TIME FACTORS;

EID: 77953020726     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.49     Document Type: Review

References (100)

1. Zhang, S. Atrial fibrillation in mainland China: epidemiology and current management. Heart 95, 1052-1055 (2009).
2. Ohsawa, M. et al. Mortality risk attributable to atrial fibrillation in middle-aged and elderly people in the Japanese general population: nineteen-year follow-up in NIPPON DATA80. Circ. J. 71, 814-819 (2007).
3. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370-2375 (2001).
4. Pieri, A. et al. Prevalence of cardiovascular risk factors among elderly Brazilians over eighty with ischemic stroke. Arq. Neuropsiquiatr. 66, 454-457 (2008).
5. Heeringa, J. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27, 949-953 (2006).
6. Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 86, 516-521 (2001).
7. Schmutz, M. et al. Low prevalence of atrial fibrillation in asymptomatic adults in Geneva, Switzerland. Europace 12, 475-481 (2010).
8. Bilato, C. et al. Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am. J. Cardiol. 104, 1092-1097 (2009).
9. Simons, L. A., Simons, J., Friedlander, Y. & McCallum, J. A comparison of risk factors for coronary heart disease and ischaemic stroke: the Dubbo study of Australian elderly. Heart Lung Circ. 18, 330-333 (2009).
10. Calkins, H. et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 9, 335-379 (2007).
11. Haïssaguerre, M. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339, 659-666 (1998).
12. Kirchhof, P. et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur. Heart J. 30, 2969c-2977c (2009).
13. Allessie, M., Ausma, J. & Schotten, U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 54, 230-246 (2002).
14. Burstein, B. & Nattel, S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 51, 802-809 (2008).
15. Burstein, B., Qi, X. Y., Yeh, Y. H., Calderone, A. & Nattel, S. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in atrial remodeling. Cardiovasc. Res. 76, 442-452 (2007).
16. Jahangir, A. et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 115, 3050-3056 (2007).
17. Lévy, S. et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99, 3028-3035 (1999).
18. Kerr, C. R. et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am. Heart J. 149, 489-496 (2005).
19. de Vos, C. B. et al. Paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J. Am. Coll. Cardiol. 55, 725-731 (2010).
20. Kopecky, S. L. et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N. Engl. J. Med. 317, 669-674 (1987).
21. Brand, F. N., Abbott, R. D., Kannel, W. B. & Wolf, P. A. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 254, 3449-3453 (1985).
22. van Walraven, C. et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch. Intern. Med. 163, 936-943 (2003).
23. Wyse, D. G. & Gersh, B. J. Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation 109, 3089-3095 (2004).
24. Saksena, S., Hettrick, D. A., Koehler, J. L., Grammatico, A. & Padeletti, L. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am. Heart J. 154, 884-892 (2007).
25. Wang, T. J. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107, 2920-2925 (2003).
26. Nerheim, P., Birger-Botkin, S., Piracha, L. & Olshansky, B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 110, 247-252 (2004).
27. Shinbane, J. S. et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J. Am. Coll. Cardiol. 29, 709-715 (1997).
28. Carlsson, J. et al. Randomized trial of ratecontrol versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 41, 1690-1696 (2003).
29. Van Gelder, I. C. et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
30. Wyse, D. G. et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
31. Roy, D. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358, 2667-2677 (2008).
32. Anter, E. & Callans, D. Pharmacological and electrical conversion of atrial fibrillation to sinus rhythm is worth the effort. Circulation 120, 1436-1443 (2009).
33. Corley, S. D. et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109, 1508-1513 (2004).
34. Guglin, M., Chen, R. & Curtis, A. B. Sinus rhythm is associated with fewer heart failure symptoms: Insights from the AFFIRM trial. Heart Rhythm doi:10.1016/j.hrthm.2010.01.003.
35. Hagens, V. E. et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am. Heart J. 149, 1106-1111 (2005).
36. European Heart Rhythm Association et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J. Am. Coll. Cardiol. 48, 854-906 (2006).
37. Reimold, S. C., Cantillon, C. O., Friedman, P. L. & Antman, E. M. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am. J. Cardiol. 71, 558-563 (1993).
38. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J. Am. Coll. Cardiol. 42, 20-29 (2003).
39. Calkins, H. et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm. Electrophysiol. 2, 349-361 (2009).
40. Dorian, P. & Mangat, I. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Card. Electrophysiol. Rev. 7, 276-279 (2003).
41. Fiala, M. et al. Termination of long-lasting persistent versus short-lasting persistent and paroxysmal atrial fibrillation by ablation. Pacing Clin. Electrophysiol. 31, 985-997 (2008).
42. Trip, M. D., Wiersinga, W. & Plomp, T. A. Incidence, predictability, and pathogenesis of amidaroneinduced thyrotoxicosis and hypothyroidism. Am. J. Med. 91, 507-511 (1991).
43. Batcher, E. L. et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am. J. Med. 120, 880-885 (2007).
44. Dusman, R. E. et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82, 51-59 (1990).
45. Torp-Pedersen, C. et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. 341, 857-865 (1999).
46. Han, F. T. et al. Results of a minimally invasive surgical pulmonary vein isolation and ganglionic plexi ablation for atrial fibrillation: single-center experience with 12-month follow-up. Circ. Arrhythm. Electrophysiol. 2, 370-377 (2009).
47. Nabauer, M. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11, 423-434 (2009).
48. Camm, A. J., Kirchhof, P., Lip, G. Y. H., Savelieva, I. & Ernst, S. in The ESC Textbook of Cardiovascular Medicine 2nd edn Ch. 29 (eds Camm, A. J., Lüscher, T. & Serruys, P. W.) 1069-1132 (Oxford University Press, 2009).
49. Li, D., Fareh, S., Leung, T. K. & Nattel, S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100, 87-95 (1999).
50. Wijffels, M. C., Kirchhof, C. J., Dorland, R. & Allessie, M. A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968 (1995).
51. Sanders, P. et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 108, 1461-1468 (2003).
52. Kannel, W. B., Wolf, P. A., Benjamin, E. J. & Levy, D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82, 2N-9N (1998). (Pubitemid 28507114)
53. Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271, 840-844 (1994).
54. Narayan, S. M., Kazi, D., Krummen, D. E. & Rappel, W. J. Repolarization and activation restitution near human pulmonary veins and atrial fibrillation initiation: a mechanism for the initiation of atrial fibrillation by premature beats. J. Am. Coll. Cardiol. 52, 1222-1230 (2008).
55. Patterson, E. et al. Spontaneous pulmonary vein firing in man: relationship to tachycardia-pause early after depolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J. Cardiovasc. Electrophysiol. 18, 1067-1075 (2007).
56. Po, S. S. et al. Rapid and stable re-entry within the pulmonary vein as a mechanism initiating paroxysmal atrial fibrillation. J. Am. Coll. Cardiol. 45, 1871-1877 (2005).
57. Gudbjartsson, D. F. et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448, 353-357 (2007).
58. Ghanem, R. N., Ramanathan, C., Jia, P. & Rudy, Y. Heart-surface reconstruction and ECG electrodes localization using fluoroscopy, epipolar geometry and stereovision: application to noninvasive imaging of cardiac electrical activity. IEEE Trans. Med. Imaging 22, 1307-1318 (2003).
59. Comprehensive Arrhythmia Research & Management Center. DE-MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation (DECAAF) [online], http:// healthsciences.utah.edu/CARMA/ DECAAF-Study.html (2010).
60. Oakes, R. S. et al. Detection and quantification of left atrial structural remodeling with delayedenhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 119, 1758-1767 (2009).
61. Li, D. et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104, 2608-2614 (2001).
62. Goette, A. et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101, 2678-2681 (2000).
63. Salehian, O. et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am. Heart J. 154, 448-453 (2007).
64. Haywood, L. J. et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J. Am. Coll. Cardiol. 54, 2023-2031 (2009).
65. Kumagai, K. et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol. 41, 2197-2204 (2003).
66. Healey, J. S. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45, 1832-1839 (2005).
67. Pedersen, O. D., Bagger, H., Køber, L. & Torp-Pedersen, C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100, 376-380 (1999).
68. Wachtell, K. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 45, 712-719 (2005).
69. Madrid, A. H. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106, 331-336 (2002).
70. GISSI-AF investigators. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606-1617 (2009).
71. Cleland, J. G. et al. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADITCRT. Eur. J. Heart Fail. 11, 1214-1219 (2009).
72. Goette, A. et al. Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design. Clin. Drug Investig. 27, 697-705 (2007).
73. Belluzzi, F. et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J. Am. Coll. Cardiol. 53, 24-29 (2009).
74. L'Allier, P. L. et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J. Am. Coll. Cardiol. 44, 159-164 (2004).
75. Patti, G. et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114, 1455-1461 (2006).
76. Adam, O., Neuberger, H. R., Böhm, M. & Laufs, U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 118, 1285-1293 (2008).
77. Calò, L. et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Cardiol. 45, 1723-1728 (2005).
78. Halonen, J. et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 297, 1562-1567 (2007).
79. Saravanan, P. et al. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ. Arrhythm. Electrophysiol. 3, 46-53 (2010).
80. Piccini, J. P. et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol. 54, 1089-1095 (2009).
81. Køber, L. et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 358, 2678-2687 (2008).
82. Hohnloser, S. H. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668-678 (2009).
83. Singh, B. N. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 357, 987-999 (2007).
84. Mason, P. K. & DiMarco, J. P. New pharmacological agents for arrhythmias. Circ. Arrhythm. Electrophysiol. 2, 588-597 (2009).
85. Comtois, P. et al. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am. J. Physiol. Heart Circ. Physiol. 295, H1489-H1504 (2008).
86. Roy, D. et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117, 1518-1525 (2008).
87. Cardiome Pharma Corporation. Cardiome announces positive phase 2b results for oral vernakalant [online], http://cardiome.com/ wordpress/?p=443 (2008).
88. Murdock, D. K., Overton, N., Kersten, M., Kaliebe, J. & Devecchi, F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol. J. 8, 175-181 (2008).
89. Scirica, B. M. et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116, 1647-1652 (2007).
90. Piccini, J. P. et al. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ. Arrhythm. Electrophysiol. 2, 626-633 (2009).
91. Shah, A. N. et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J. Cardiovasc. Electrophysiol. 19, 661-667 (2008).
92. Jiang, C. Y. et al. Early detection of pulmonary vein reconnection after isolation in patients with paroxysmal atrial fibrillation: a comparison of ATP-induction and reassessment at 30 minutes postisolation. J. Cardiovasc. Electrophysiol. 20, 1382-1387 (2009).
93. Sauer, W. H. et al. Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm 3, 1024-1028 (2006).
94. Cappato, R. et al. Prospective assessment of late conduction recurrence across radiofrequency lesions producing electrical disconnection at the pulmonary vein ostium in patients with atrial fibrillation. Circulation 108, 1599-1604 (2003).
95. Knecht, S. et al. Left atrial linear lesions are required for successful treatment of persistent atrial fibrillation. Eur. Heart J. 29, 2359-2366 (2008).
96. Cappato, R. et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3, 32-38 (2010).
97. Fonarow, G. C. et al. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation 121, 879-891 (2010).
98. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
99. Albers, G. W. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293, 690-698 (2005).
100. European Heart Rhythm Association (EHRA) et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4, 816-861 (2007).